Zhifei Biological: Subsidiary Degu Insulin Injection Production Registration Application Accepted

2026-03-04 08:24:50

Abstract generation in progress

Recently, Zhifei Biological announced that its wholly-owned subsidiary, Chongqing Chen’an Biopharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the production registration of Teglud Insulin Injection.

Teglud Insulin is a long-acting insulin analog with a significantly extended duration of action, offering stable blood sugar reduction and low blood glucose variability. It is administered once daily via subcutaneous injection and is suitable for the treatment of adult type 2 diabetes.

The announcement states that Phase III clinical trial data for Teglud Insulin Injection show that the company’s developed product has comparable clinical efficacy and safety to the original product, NovoNordisk’s NovoRapid®. As of the date of this announcement, besides the original drug, one domestic company has also received approval to market Teglud Insulin Injection.

(Zhifei Biological Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes